Effects of Hyperlipidemia on the Pharmacokinetics of Tofacitinib, a JAK 1/3 Inhibitor, in Rats
Tofacitinib, an inhibitor of Janus kinases (JAKs) 1 and 3, has been shown to be effective in the treatment of rheumatoid arthritis. The incidence of hyperlipidemia has been found to be higher in patients with rheumatoid arthritis. The present study therefore investigated the pharmacokinetics of tofa...
Gardado en:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
MDPI AG
2023-08-01
|
| Series: | Pharmaceutics |
| Assuntos: | |
| Acceso en liña: | https://www.mdpi.com/1999-4923/15/9/2195 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|